{
  "analyst_run_id": "RUN-20260715-600276-20260715045841549715-a06a368e",
  "decision": {
    "chase_limit": 58.5,
    "decision": "BUY",
    "entry_max": 57.8,
    "entry_min": 57.0,
    "invalid_conditions": [
      "次日低开超2%；跌破56元；成交量较前日萎缩超30%；创新药板块指数跌幅超1%"
    ],
    "main_theme": "创新药",
    "position_limit": 0.2,
    "raw": {
      "chase_limit": 58.5,
      "decision": "BUY",
      "entry_max": 57.8,
      "entry_min": 57.0,
      "evidence_ids": [
        "EVD-3ca8534cc7f3d4f4",
        "EVD-bed1cd27fcbe95a1",
        "EVD-cdaf22fff6eef444",
        "EVD-bf4e7a9e2d77f70e",
        "EVD-24de1c4a19c43ad4",
        "EVD-1633902c6cbba5e7",
        "EVD-67db64ca05505bb3",
        "EVD-077cf2a882da8a0f"
      ],
      "invalid_conditions": "次日低开超2%；跌破56元；成交量较前日萎缩超30%；创新药板块指数跌幅超1%",
      "main_theme": "创新药",
      "position_limit": 0.2,
      "risk_notes": "突破有效性待验证；大盘环境偏弱；游资缺席可能导致短线爆发力不足；注意止盈止损。",
      "score": 55.73,
      "setup": "LOW_VOLUME_BREAKOUT",
      "stock_name": "恒瑞医药",
      "stop_loss": 55.5,
      "summary": "创新药主题发酵，基本面扎实，机构一致看好，技术面短期强势但中期趋势偏弱，低量突破需确认，总体风险可控，建议轻仓参与。",
      "target_1": 60.0,
      "target_2": 62.0,
      "ticker": "600276"
    },
    "risk_notes": [
      "突破有效性待验证；大盘环境偏弱；游资缺席可能导致短线爆发力不足；注意止盈止损。"
    ],
    "score": 55.73,
    "setup": "LOW_VOLUME_BREAKOUT",
    "stock_name": "恒瑞医药",
    "stop_loss": 55.5,
    "summary": "创新药主题发酵，基本面扎实，机构一致看好，技术面短期强势但中期趋势偏弱，低量突破需确认，总体风险可控，建议轻仓参与。",
    "target_1": 60.0,
    "target_2": 62.0,
    "ticker": "600276"
  },
  "report_ids": [
    "REPORT-20260715045904720715-784ce8ea52f8",
    "REPORT-20260715045920756898-39deefb24acf",
    "REPORT-20260715045952631297-a9df8b0d6f51",
    "REPORT-20260715050008736764-0d4a70fad551",
    "REPORT-20260715050016401258-bd95fd3b9a57",
    "REPORT-20260715050031628738-f6087a5c7565",
    "REPORT-20260715050038836393-20ee2c9b84d6",
    "REPORT-20260715050048816145-10934e5b8ebe",
    "REPORT-20260715050110225646-4ac838ed211d",
    "REPORT-20260715050137367528-398fc0b91e9a",
    "REPORT-20260715050150543996-753ddf4e6b22"
  ],
  "risk": {
    "evidence_ids": [
      "EVD-3ca8534cc7f3d4f4",
      "EVD-bed1cd27fcbe95a1",
      "EVD-cdaf22fff6eef444",
      "EVD-bf4e7a9e2d77f70e",
      "EVD-24de1c4a19c43ad4",
      "EVD-1633902c6cbba5e7",
      "EVD-67db64ca05505bb3",
      "EVD-077cf2a882da8a0f"
    ],
    "risk_penalty": 5,
    "summary": "恒瑞医药(600276)基本面优异，创新药主题发酵，机构一致看好，但技术面低量突破有效性待验证，中期趋势偏弱，游资参与缺失，个股缺乏直接催化，且大盘环境一般，存在突破失败和主题退潮风险。",
    "veto": []
  }
}